Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew P Grieve

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Pharmaceutical Statistics|February 23, 2021
Optimising the trade-off between type I and II error rates in the Bayesian contextRosalind J Walley, Andrew P Grieve
Journal of Clinical Epidemiology|September 10, 2013
Limitations of within-person study designs. In replyJennifer M Nicholas, Andrew P Grieve, Martin C Gulliford
Biometrical Journal. Biometrische Zeitschrift|March 23, 2016
The predictive distribution of the residual variability in the linear-fixed effects model for clinical cross-over trialsAnja Bertsche, Gerhard Nehmiz, Jan Beyersmann, et al.
Journal of Clinical Epidemiology|December 27, 2011
Within-person study designs had lower precision and greater susceptibility to bias because of trends in exposure than cohort and nested case-control designsJennifer M Nicholas, Andrew P Grieve, Martin C Gulliford
Journal of Biopharmaceutical Statistics|November 21, 2007
Flexible design and efficient implementation of adaptive dose-finding studiesChristopher J Weir, David J Spiegelhalter, Andrew P Grieve
Pharmaceutical Statistics|February 17, 2017
Statistical issues in first-in-human studies on BIA 10-2474: Neglected comparison of protocol against practiceSheila M Bird, Rosemary A Bailey, Andrew P Grieve, et al.
Pharmaceutical Statistics|November 4, 2006
Implementation of a Bayesian adaptive design in a proof of concept studyMichael K Smith, Ieuan Jones, Mark F Morris, et al.
Stroke|October 18, 2003
Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic strokeMichael Krams, Kennedy R Lees, Werner Hacke, et al.
Journal of Biopharmaceutical Statistics|November 21, 2007
Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshopMichael Krams, Carl-Fredrik Burman, Vladimir Dragalin, et al.
Stroke|April 2, 2011
Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysisKeerthi M Mohan, Charles D A Wolfe, Anthony G Rudd, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Pharmaceutical Statistics|February 23, 2021
Optimising the trade-off between type I and II error rates in the Bayesian contextRosalind J Walley, Andrew P Grieve
Journal of Clinical Epidemiology|September 10, 2013
Limitations of within-person study designs. In replyJennifer M Nicholas, Andrew P Grieve, Martin C Gulliford
Biometrical Journal. Biometrische Zeitschrift|March 23, 2016
The predictive distribution of the residual variability in the linear-fixed effects model for clinical cross-over trialsAnja Bertsche, Gerhard Nehmiz, Jan Beyersmann, et al.
Journal of Clinical Epidemiology|December 27, 2011
Within-person study designs had lower precision and greater susceptibility to bias because of trends in exposure than cohort and nested case-control designsJennifer M Nicholas, Andrew P Grieve, Martin C Gulliford
Journal of Biopharmaceutical Statistics|November 21, 2007
Flexible design and efficient implementation of adaptive dose-finding studiesChristopher J Weir, David J Spiegelhalter, Andrew P Grieve
Pharmaceutical Statistics|February 17, 2017
Statistical issues in first-in-human studies on BIA 10-2474: Neglected comparison of protocol against practiceSheila M Bird, Rosemary A Bailey, Andrew P Grieve, et al.
Pharmaceutical Statistics|November 4, 2006
Implementation of a Bayesian adaptive design in a proof of concept studyMichael K Smith, Ieuan Jones, Mark F Morris, et al.
Stroke|October 18, 2003
Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic strokeMichael Krams, Kennedy R Lees, Werner Hacke, et al.
Journal of Biopharmaceutical Statistics|November 21, 2007
Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshopMichael Krams, Carl-Fredrik Burman, Vladimir Dragalin, et al.
Stroke|April 2, 2011
Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysisKeerthi M Mohan, Charles D A Wolfe, Anthony G Rudd, et al.
Pageof 3